Skip to main content
. 2016 Feb 21;7(13):15959–15976. doi: 10.18632/oncotarget.7557

Figure 2. Chronic dosing of AZD5363 decreases tumor burden in PTEN-deficient models of prostate cancer.

Figure 2

Twenty-week-old PTEN-KO mice with CNPC or CRPC were randomized (n = 8 per group) and treated vehicle (control) or AZD5363 (100 mg/kg b.i.d.) for 4 weeks. Representative images of GUTs en bloc and corresponding waterfall plots of individual treatment responses for CNPC A., and CRPC B. Prostate tumors are indicated by yellow mask. Plots of overall tumor burden measured bu tumor area for CNPC C., and CRPC D. Values represent mean ± s.e.